# GLP-1 Receptor Pharmacology and the Semaglutide Trial Record > Semaglutide mechanism of action, STEP weight-loss trials, SELECT cardiovascular data, and the 2024-2025 FLOW and ESSENCE findings — all findings cited to primary sources. ## Semaglutide Mechanism of Action Semaglutide activates GLP-1 receptors on pancreatic beta cells via the cAMP/PKA pathway, triggering glucose-dependent insulin secretion — meaning insulin release is stimulated only when blood glucose is elevated [10]. Simultaneously, it suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output. Gastric emptying is slowed through vagal GLP-1 receptor signaling. The molecule reaches the brain via circumventricular organs rather than crossing the intact BBB. Once at the arcuate nucleus, semaglutide directly activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons [9]. Rodent studies identified ten additional brain regions activated by semaglutide, including the parabrachial nucleus, suggesting a distributed central appetite-suppression network [9]. Food preference data from rodent studies show semaglutide reduces intake of high-fat foods specifically, with no reduction in metabolic energy expenditure [9]. ## Semaglutide Appetite Suppression Mechanism Semaglutide reduces food intake through both central and peripheral mechanisms. Centrally, it activates POMC/CART neurons while simultaneously inhibiting NPY/AgRP neurons [9]. Peripherally, slowed gastric emptying extends the sense of fullness after meals. The DXA STEP 1 substudy confirmed 27.4% visceral fat mass reduction at 68 weeks [11]. ## Semaglutide for Weight Loss: Clinical Trial Evidence Across the STEP program, semaglutide 2.4 mg once weekly produced consistent weight reductions: - STEP 1 (n=1,961, adults without T2DM): -14.9% mean weight loss vs -2.4% placebo at 68 weeks [1] - STEP 2 (n=1,210, adults with T2DM): -9.6% vs -3.4% placebo at 68 weeks [4] - STEP 4 (n=803, discontinuation design): +6.9% regain after placebo switch vs -7.9% continued semaglutide [3] - STEP 5 (n=304, two-year): -15.2% vs -2.6% placebo at week 104 [2] - STEP TEENS (n=201, adolescents 12-18): -16.1% BMI reduction vs +0.6% with placebo at 68 weeks [21] ## Semaglutide and Visceral Fat Reduction Semaglutide 2.4 mg reduced visceral fat mass by 27.4% at week 68 in the DXA exploratory substudy of STEP 1 [11]. Total fat mass declined by 19.3%. Lean body mass proportion relative to total mass increased by 3.0 percentage points despite an absolute decline in lean mass [11]. ## Weight Regain After Semaglutide Cessation Discontinuation after a 20-week run-in phase in STEP 4 (n=803) resulted in mean weight regain of +6.9% by week 68 [3]. Those maintained on semaglutide continued losing, reaching -7.9% by week 68. Cardiometabolic improvements — waist circumference, blood pressure, HbA1c — all reversed in the placebo-switch arm. ## Semaglutide Cardiovascular Outcomes Research Semaglutide 2.4 mg reduced MACE by 20% in the SELECT trial (n=17,604; median 39.8 months) in adults with obesity or overweight and established cardiovascular disease but without type 2 diabetes [5]. HR 0.80 (95% CI 0.72-0.90; p<0.001). SUSTAIN-6 (n=3,297): HR 0.74 (95% CI 0.58-0.95) for MACE at two years [6]. PIONEER 6 (n=3,183): all-cause mortality 49% lower with oral semaglutide versus placebo (HR 0.51; p=0.008) [7]. ## Emerging Indications Under Investigation The FLOW trial (n=3,533; median 3.4 years) reduced major kidney outcomes and cardiovascular death by 24% in adults with type 2 diabetes and CKD [19]. HR 0.76 (95% CI 0.66-0.88; p<0.001). Trial stopped early for efficacy. The ESSENCE trial: MASH resolution without worsening fibrosis in 62.9% vs 34.3% placebo at 72 weeks [20]. FDA granted accelerated approval August 15, 2025. Semaglutide in AUD: 9-week RCT (n=48) found semaglutide titrated to 1.0 mg weekly significantly reduced alcohol self-administration and craving versus placebo [18]. ## Semaglutide vs Tirzepatide: Comparative Research Overview SURPASS-2 (n=1,879, T2DM): All three tirzepatide doses superior to semaglutide 1 mg for HbA1c; tirzepatide 15 mg achieved -11.2 kg vs -5.7 kg with semaglutide 1 mg [17]. SURMOUNT-5 (n=751, obesity without T2DM): Tirzepatide achieved 20.2% mean weight loss versus 13.7% with semaglutide over 72 weeks [16]. GI discontinuations more common in semaglutide arm (5.6% vs 2.7%). ## References [1] Wilding JPH et al. STEP 1. N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 [2] Garvey WT et al. STEP 5. Nat Med. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556320/ [3] Rubino D et al. STEP 4. JAMA. 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/ [4] Davies M et al. STEP 2. Lancet. 2021;397:971-984. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract [5] Lincoff AM et al. SELECT. N Engl J Med. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 [6] Marso SP et al. SUSTAIN-6. N Engl J Med. 2016;375:1834-1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 [7] Husain M et al. PIONEER 6. N Engl J Med. 2019. https://www.nejm.org/doi/full/10.1056/NEJMoa1901118 [8] Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide. Drug Des Devel Ther. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11215664/ [9] Gabery S et al. Semaglutide lowers body weight via distributed neural pathways. JCI Insight. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7213778/ [10] Papakonstantinou I et al. Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11674233/ [11] Wilding JPH et al. STEP 1 DXA substudy. J Endocr Soc. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/ [16] Wadden TA et al. SURMOUNT-5. N Engl J Med. 2025. https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394 [17] Frías JP et al. SURPASS-2. N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519 [18] Hendershot CS et al. Semaglutide in AUD. JAMA Psychiatry. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/ [19] Perkovic V et al. FLOW. N Engl J Med. 2024;391:109-121. https://www.nejm.org/doi/10.1056/NEJMoa2403347 [20] Sanyal AJ et al. ESSENCE. N Engl J Med. 2025;392(21):2089-2099. https://www.prnewswire.com/news-releases/essence-phase-3-trial-of-semaglutide-showed-significant-improvements-at-72-weeks-in-adults-with-mash-published-in-nejm-302443359.html [21] Weghuber D et al. STEP TEENS. N Engl J Med. 2022;387(24):2245-2257. https://www.nejm.org/doi/full/10.1056/NEJMoa2208601 --- Clinical trial record for one compound — semaglutide — read from the primary sources and indexed here. Not a prescriber, not a vendor.